On March 2, 2017 Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Fleximer platform technology, reported that it will present data on its lead preclinical immunoconjugate, XMT-1522, at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017 in Washington, D.C (Press release, Mersana Therapeutics, MAR 2, 2017, View Source [SID1234517971]). The two poster presentations will highlight results from ongoing non-clinical studies where the compound was evaluated as a potential combination partner with immunomodulatory cancer therapies and it was also characterized for its pharmacokinetics, metabolism and biodistribution in tumor-bearing mice. Schedule your 30 min Free 1stOncology Demo!
The accepted abstracts are listed below and are now available online on the AACR (Free AACR Whitepaper) 2017 conference website: www.aacr.org
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract Control Number: 6879
Title: Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models
Authors: Natasha Bodyak, Marina Protopopova, Qingxiu Zhang, Alex Yurkovetskiy, Mao Yin, LiuLiang Qin, Laura L Poling, Rebecca Mosher, Donald A. Bergstrom, Timothy B. Lowinger
Session Category: Immunology
Session Title: Immune Response to Hematopoietic Tumors: New Developments in Tumor Immunology
Session Date and Time: Monday Apr 3, 2017 1:00 PM – 5:00 PM
Location: Convention Center, Halls A-C, Poster Section 26
Poster Board Number: 29
Abstract control number: 6716
Title: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate.
Authors: Donald A. Bergstrom, Natalya Bodyak, Alex Yurkovetskiy, Michael DeVit, Mao Yin, Laura L. Poling, Joshua D. Thomas, Dmitry Gumerov, Dongmei Xiao, Elena Ter-Ovanesyan, Charlie Bu, LiuLiang Qin, Alex Uttard, Alex Johnson, Timothy B. Lowinger
Session Category: Experimental and Molecular Therapeutics
Session Date and Time: Sunday Apr 2, 2017 1:00 PM – 5:00 PM
Location: Convention Center, Halls A-C, Poster Section 26
Poster Board Number: 29
About XMT-1522
XMT-1522 incorporates a novel, proprietary HER2 antibody, which is conjugated with Mersana’s Dolaflexin platform which includes its Fleximer technology and proprietary auristatin payload. XMT-1522 provides a drug load of approximately 12-15 molecules per antibody, specifically designed to improve potency while simultaneously increasing tolerability. XMT-1522 has the potential to extend HER2-targeted therapy beyond the current "HER2-positive" populations into patients with lower levels of HER2 expression.